These data, specifically the increase in bile acid receptor Fxr gene expression without the concomitant increase in Shp, its downstream target, suggest a role of early dysbiosis in impairment of the FXR-SHP pathway, which has been reported in NAFLD and warrants further exploration. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.